

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CStone Pharmaceuticals**

**基石藥業**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2616)**

## **ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES**

This announcement is made by CStone Pharmaceuticals (the “**Company**,” together with its subsidiaries, collectively referred to as the “**Group**”) in accordance with Rule 13.51B(2) and Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to the regulatory announcement published by the Stock Exchange on June 11, 2025 in relation to the disciplinary actions taken by the Stock Exchange against New Century Healthcare Holding Co. Limited (Stock Code: 1518) (“**New Century Healthcare**”) and its six directors (the “**Regulatory Announcement**”). According to the Regulatory Announcement, the Stock Exchange has publicly criticized Mr. Sun Hongbin (“**Mr. Sun**”) (who is also an independent non-executive director of the Company) (the “**Criticism**”) for certain aspects of his conduct during his tenure as an independent non-executive director of New Century Healthcare which the Stock Exchange found to constitute a violation of Rule 3.08 and Rule 3.09B(2) of the Listing Rules. Further details about the disciplinary actions and the investigation findings are provided in the Regulatory Announcement. According to the Regulatory Announcement, Mr. Sun is required to complete 15 hours of training within 90 days, including at least three hours on each of directors’ duties and the Corporate Governance Code.

Mr. Sun is an independent non-executive director of the Company, the chairman of the Audit Committee, and a member of the Nomination Committee and the Investment Committee. He does not participate in the day-to-day operations of the Company. The board of directors (the “**Board**”) of the Company has carefully assessed the Criticism against Mr. Sun set out in the Regulatory Announcement. To the best knowledge and belief of the Board, the Criticism is irrelevant to the affairs of the Group and will not have an adverse impact on the business and/or operations of the Group. The Board also will keep abreast of the development of such incident and carefully assess Mr. Sun’s eligibility to serve as an independent non-executive director of the Company.

By order of the Board  
**CStone Pharmaceuticals**  
**Dr. Wei Li**  
*Chairman*

Suzhou, the People’s Republic of China, June 13, 2025

*As at the date of this announcement, the board of directors of the Company comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu, Mr. Hongbin Sun and Ms. Yip Betty Ho as independent non-executive directors.*